New hope for kidney transplant patients: belatacept trial targets hidden rejection

NCT ID NCT06291103

Not yet recruiting Disease control Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether switching to belatacept (a drug) plus standard care can better treat early antibody-mediated rejection in kidney transplant patients compared to continuing standard care alone. About 290 adults with new donor-specific antibodies but no kidney function decline will be randomly assigned to one of two groups. The goal is to see if belatacept helps prevent graft damage and rejection over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Belatacept
What this could lead to: If successful, this could offer a better way to treat early rejection in kidney transplant patients, potentially improving long-term graft survival.
What could go wrong: This is an early-phase trial with a moderate size, so results may not confirm benefit. Belatacept also requires lifelong use alongside other drugs, and risks include infection and graft loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT REJECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANT REJECTION

Contacts and locations

Locations

CHU de ROUEN

Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.